PIA
CBMG

Piedmont Investment Advisors’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Piedmont Investment Advisors’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-201
Closed -$4K – 2679
2018
Q2 		$4K Buy
+201
New +$3.77K ﹤0.01% 2313

Other funds holding CBMG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Piedmont Investment Advisors's CBMG Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2018, closing a stake of 201 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in CBMG in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 38 funds tracked by Wall St. Rank hold CBMG as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 201 Cellular Biomedicine Group, Inc. shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Cellular Biomedicine Group, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Cellular Biomedicine Group, Inc. position peaked at $4K in Q2 2018.
  • 38 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.